NanoViricides (NNVC) signed a Master Services Agreementwith Only Orphans Cote, a regulatory consultant firm founded by Dr. Timothy Cote. Dr. Cote and OOC will help the Company formulate its orphan drug strategy for NV-387, as well as develop relevant orphan drug designation applications and prosecute these applications at the US FDA Office of Orphan Products.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC:
- NanoViricides Holds 2025 Annual Stockholders Meeting
- NanoViricides reports Q3 EPS (10c) vs. (23c) last year
- NanoViricides Secures $6 Million Through Securities Offering
- NanoViricides prices 3.57M shares at $1.68 in registered direct offering
- NanoViricides receives approval to start Phase II trial of NV-387